JP2019510807A5 - - Google Patents

Download PDF

Info

Publication number
JP2019510807A5
JP2019510807A5 JP2018553149A JP2018553149A JP2019510807A5 JP 2019510807 A5 JP2019510807 A5 JP 2019510807A5 JP 2018553149 A JP2018553149 A JP 2018553149A JP 2018553149 A JP2018553149 A JP 2018553149A JP 2019510807 A5 JP2019510807 A5 JP 2019510807A5
Authority
JP
Japan
Prior art keywords
bchl
mdsc
inhibitor
mdsc inhibitor
rgd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018553149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510807A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2017/050440 external-priority patent/WO2017179053A1/en
Publication of JP2019510807A publication Critical patent/JP2019510807A/ja
Publication of JP2019510807A5 publication Critical patent/JP2019510807A5/ja
Priority to JP2021193514A priority Critical patent/JP2022031823A/ja
Pending legal-status Critical Current

Links

JP2018553149A 2016-04-10 2017-04-10 バクテリオクロロフィル誘導体を含む、がんの治療のための併用療法 Pending JP2019510807A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021193514A JP2022031823A (ja) 2016-04-10 2021-11-29 バクテリオクロロフィル誘導体を含む、がんの治療のための併用療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662320549P 2016-04-10 2016-04-10
US62/320,549 2016-04-10
PCT/IL2017/050440 WO2017179053A1 (en) 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021193514A Division JP2022031823A (ja) 2016-04-10 2021-11-29 バクテリオクロロフィル誘導体を含む、がんの治療のための併用療法

Publications (2)

Publication Number Publication Date
JP2019510807A JP2019510807A (ja) 2019-04-18
JP2019510807A5 true JP2019510807A5 (pt-PT) 2020-05-14

Family

ID=58794130

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018553149A Pending JP2019510807A (ja) 2016-04-10 2017-04-10 バクテリオクロロフィル誘導体を含む、がんの治療のための併用療法
JP2021193514A Pending JP2022031823A (ja) 2016-04-10 2021-11-29 バクテリオクロロフィル誘導体を含む、がんの治療のための併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021193514A Pending JP2022031823A (ja) 2016-04-10 2021-11-29 バクテリオクロロフィル誘導体を含む、がんの治療のための併用療法

Country Status (14)

Country Link
US (2) US11278555B2 (pt-PT)
EP (1) EP3442582A1 (pt-PT)
JP (2) JP2019510807A (pt-PT)
KR (2) KR20190008206A (pt-PT)
CN (2) CN118304400A (pt-PT)
AU (2) AU2017250732B2 (pt-PT)
BR (1) BR112018070847A2 (pt-PT)
CA (1) CA3020067A1 (pt-PT)
IL (1) IL262191A (pt-PT)
MX (2) MX2018012392A (pt-PT)
RU (2) RU2747258C2 (pt-PT)
SG (1) SG11201808849TA (pt-PT)
WO (1) WO2017179053A1 (pt-PT)
ZA (1) ZA201807187B (pt-PT)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10107240B2 (en) 2014-04-04 2018-10-23 Dayco Ip Holdings, Llc Check valves and Venturi devices having the same
EP3148852B1 (en) 2014-05-30 2021-03-24 Dayco IP Holdings, LLC Vacuum creation system having an ejector, pneumatic control valve and optionally an aspirator
EP3723785A1 (en) * 2017-12-17 2020-10-21 Yeda Research and Development Co. Ltd Cop9 signalosome (csn) complex modulators and uses thereof
WO2022149934A1 (ko) * 2021-01-08 2022-07-14 가톨릭대학교 산학협력단 암세포의 항암 면역치료를 위한 항체-폴리에틸렌글리콜-광감각제 접합체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1137411B1 (en) 1998-12-09 2006-12-06 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Palladium-substituted bacteriochlorophyll derivatives and use thereof
IL133253A0 (en) * 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
IL152900A0 (en) * 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
ES2763237T3 (es) 2006-08-23 2020-05-27 Yeda Res & Dev Conjugados de péptidos de RGD y fotosensibilizantes de (bacterio)clorofila y sus usos
JP5773495B2 (ja) 2008-10-23 2015-09-02 ステバ バイオテック、エス.エイ. Rgd含有ペプチド模倣体及びその使用
US9249087B2 (en) 2011-02-01 2016-02-02 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
TWI442945B (zh) 2011-05-18 2014-07-01 Univ Nat Taiwan 雙效微脂體用於治療的方法
WO2014141289A1 (en) * 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University Photo - chemo composition on the basis of microcapsules with a core -shell structure

Similar Documents

Publication Publication Date Title
JP2019510807A5 (pt-PT)
JP2020128432A (ja) がんの処置のための併用治療
AU2022202392A1 (en) Combination therapies of HDAC inhibitors and PD-1 inhibitors
HRP20210200T1 (hr) Kombinirana antitumorska imunoterapija
ES2617983T3 (es) Terapia de combinación que incluye anticuerpos de unión a antígenos asociados a tumores
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
NZ602635A (en) Methods of enhancing drug delivery and effectiveness of therapeutic agents
JP2018529780A5 (pt-PT)
JP2020523354A5 (pt-PT)
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
Kim et al. Procarbazine and CCNU chemotherapy for recurrent glioblastoma with MGMT promoter methylation
JP2016515586A5 (pt-PT)
MX2018002932A (es) Sintesis y composicion de agentes terapeuticos fotodinamicos para el tratamiento dirigido del cancer.
PH12020500666A1 (en) Pladienolide compounds and their use
CY1123861T1 (el) Θεραπευτικη αντιμετωπιση εξαψεων και οστικης απωλειας, επαγομενων απο θεραπεια στερησης ανδρογονων, με χρηση cis-κλομιφαινης
MX2022012351A (es) Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres.
RU2021110230A (ru) Комбинированные способы терапии для лечения злокачественной опухоли
MX2021003842A (es) Terapia combinada para el tratamiento del cancer.
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
Li et al. The role of raltitrexed/cisplatin with concurrent radiation therapy in treating advanced cervical cancer.
JP2016509050A5 (pt-PT)
Marcu Improving Therapeutic Ratio in Head and Neck Cancer with Adjuvant and Cisplatin‐Based Treatments
WO2021262562A3 (en) Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof
Jackson et al. Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer